Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

756.30INR
20 Sep 2019
Change (% chg)

Rs15.05 (+2.03%)
Prev Close
Rs741.25
Open
Rs747.70
Day's High
Rs758.85
Day's Low
Rs734.15
Volume
2,689,710
Avg. Vol
1,570,793
52-wk High
Rs931.50
52-wk Low
Rs697.20

Latest Key Developments (Source: Significant Developments)

Lupin Says U.S. FDA Issues Warning Letter For Co's Mandideep Facility
Thursday, 19 Sep 2019 

Sept 19 (Reuters) - Lupin Ltd ::LUPIN LTD - U.S. FDA ISSUES WARNING LETTER FOR COMPANY'S MANDIDEEP FACILITY.LUPIN LTD - THERE ARE NO DMF AND ANDA APPLICATIONS PENDING REVIEW OR APPROVAL FROM MANDIDEEP FACILITY.LUPIN LTD - DOES NOT BELIEVE THAT WARNING LETTER WILL HAVE AN IMPACT ON DISRUPTION OF SUPPLIES OR EXISTING REVENUES FROM OPERATIONS OF FACILITY.  Full Article

Lupin South Africa Unit In Commercial Deal With Creso For Hemp Oil-Based Cannaqix
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Lupin Ltd ::SAYS ITS SUBSIDIARY IN SOUTH AFRICA ANNOUNCES COMMERCIAL AGREEMENT WITH CRESO PHARMA FOR HEMP OIL BASED CANNAQIX.  Full Article

India's Lupin June-Quarter Consol Net Profit Rises
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Lupin Ltd ::JUNE QUARTER CONSOL NET PROFIT 3.03 BILLION RUPEES VERSUS PROFIT OF 2.03 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR JUNE QUARTER CONSOL PROFIT WAS 3.30 BILLION RUPEES.JUNE QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 44.18 BILLION RUPEES VERSUS 38.56 BILLION RUPEES LAST YEAR.  Full Article

Lupin Launches Imatinib Mesylate Tablets
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Lupin Ltd ::"LUPIN LAUNCHES IMATINIB MESYLATE TABLETS"..  Full Article

Lupin Gets U.S. FDA Approval For Cinacalcet Tablets
Wednesday, 3 Jul 2019 

July 3 (Reuters) - Lupin Ltd ::GETS U.S. FDA APPROVAL FOR CINACALCET TABLETS.  Full Article

Lupin Gets Tentative U.S. FDA Nod For Fosaprepitant For Injection
Tuesday, 7 May 2019 

May 7 (Reuters) - Lupin Ltd ::LUPIN RECEIVES TENTATIVE U.S. FDA APPROVAL FOR FOSAPREPITANT FOR INJECTION.  Full Article

Lupin Ltd Says U.S. FDA Classifies Inspection Of Pithampur Unit-2 As OAI
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Lupin Ltd ::U.S. FDA CLASSIFIES INSPECTION OF LUPIN''S PITHAMPUR (INDORE) UNIT-2 FACILITY AS OAI.U.S. FDA STATES THAT FACILITY MAY BE SUBJECT TO REGULATORY OR ADMINISTRATIVE ACTION.U.S. FDA SAYS THAT IT MAY WITHHOLD APPROVAL OF ANY PENDING APPLICATIONS OR SUPPLEMENTS IN WHICH THIS FACILITY IS LISTED.DOES NOT BELIEVE THAT THIS CLASSIFICATION WILL IMPACT EXISTING REVENUES FROM OPERATIONS OF THIS FACILITY.CO IS IN PROCESS OF SENDING FURTHER UPDATES OF ITS CORRECTIVE ACTIONS TO THE U.S. FDA.  Full Article

Lupin Gets FDA Approval For Fluoxetine Tablets USP
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Lupin Ltd ::RECEIVES FDA APPROVAL FOR FLUOXETINE TABLETS USP.  Full Article

Lupin Ltd Says Lupin Bioresearch Centre Completes Fifth Successful U.S. FDA Inspection
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Lupin Ltd ::LUPIN BIORESEARCH CENTRE COMPLETES FIFTH SUCCESSFUL U.S. FDA INSPECTION.SUCCESSFUL COMPLETION OF U.S FDA INSPECTION AT ITS LUPIN BIORESEARCH CENTRE (LBC) WITHOUT ANY OBSERVATIONS.  Full Article

Lupin Says Pithampur Unit-3 Gets EIR From U.S. FDA
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Lupin Ltd ::PITHAMPUR UNIT-3 GETS EIR FROM U.S. FDA.SAYS INSPECTION WAS CONDUCTED BETWEEN OCTOBER 8, 2018 TO OCTOBER 18, 2018.LUPIN - PITHAMPUR UNIT-3 IS INVOLVED IN MANUFACTURE OF METERED DOSE INHALERS, DRY POWDER INHALERS AND TOPICAL FORMULATIONS FOR REGULATED MARKETS.  Full Article

BUZZ-Lupin falls after U.S. FDA classification of Goa plant, potential approval curbs

** Indian drugmaker Lupin Ltd's shares fall as much as 5.7% to 720 rupees - lowest since March 28